Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Haemophilus influenzae Type B Infections Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Haemophilus influenzae Type B Infections Overview | 9 | 1 |
| Pipeline Products for Haemophilus influenzae Type B Infections Comparative Analysis | 10 | 1 |
| Haemophilus influenzae Type B Infections Therapeutics under Development by Companies | 11 | 1 |
| Haemophilus influenzae Type B Infections Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Haemophilus influenzae Type B Infections Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Haemophilus influenzae Type B Infections Products under Development by Companies | 16 | 2 |
| Haemophilus influenzae Type B Infections Products under Investigation by Universities/Institutes | 18 | 1 |
| Haemophilus influenzae Type B Infections Companies Involved in Therapeutics Development | 19 | 10 |
| Beijing Minhai Biotechnology Co., Ltd | 19 | 1 |
| Biological E. Limited | 20 | 1 |
| Daiichi Sankyo Company, Limited | 21 | 1 |
| Indian Immunologicals Limited | 22 | 1 |
| Kaketsuken K.K. | 23 | 1 |
| LG Life Science LTD. | 24 | 1 |
| Panacea Biotec Limited | 25 | 1 |
| Sanofi Pasteur SA | 26 | 1 |
| Sinovac Biotech Ltd. | 27 | 1 |
| Zydus Cadila Healthcare Limited | 28 | 1 |
| Haemophilus influenzae Type B Infections Therapeutics Assessment | 29 | 8 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Combination Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 22 |
| (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile | 37 | 1 |
| (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile | 38 | 1 |
| (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile | 39 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile | 40 | 1 |
| (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile | 41 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 42 | 1 |
| (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 43 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile | 44 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile | 45 | 1 |
| (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile | 46 | 2 |
| (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine Drug Profile | 48 | 1 |
| (meningococcal + Haemophilus influenzae [serotype B]) vaccine Drug Profile | 49 | 1 |
| Eupenta Drug Profile | 50 | 1 |
| haemophilus influenzae B vaccine Drug Profile | 51 | 1 |
| Haemophilus influenzae B vaccine Drug Profile | 52 | 1 |
| Haemophilus influenzae B vaccine Drug Profile | 53 | 1 |
| hemophilus influenza [serotype B] vaccine Drug Profile | 54 | 1 |
| KD-370 Drug Profile | 55 | 1 |
| LT-Hib Drug Profile | 56 | 1 |
| NU-300 Drug Profile | 57 | 1 |
| VN-0105 Drug Profile | 58 | 1 |
| Haemophilus influenzae Type B Infections Dormant Projects | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |